3 Pumps and Valves Maker, Pharma Excipients Maker and Two Wheelers Maker Stocks With a Strong Future Roadmap: Kirloskar Brothers, Sudeep Pharma and Hero MotoCorp
- November 10, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Kirloskar Brothers, Sudeep Pharma and Hero MotoCorp: ROE of 15.2% to 26.6% and FY22 to FY26 revenue CAGR of 10.5% to 17.6%. Prices as of 9 Nov 2026.
Quick Answer
The three pump, excipient and commuter bike stocks to watch are Kirloskar Brothers, Sudeep Pharma and Hero MotoCorp. Their return on equity ranges from 15.2% to 26.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.5% to 17.6%. Hero MotoCorp has the highest return on equity at 26.6%, while Sudeep Pharma has the fastest revenue growth at 17.6% a year. Prices are based on the 9 November 2026 close, and this article is educational, not investment advice.
Pump, excipient and commuter bike stocks let investors follow companies that serve a growing part of the Indian economy. Kirloskar Brothers, Sudeep Pharma and Hero MotoCorp cover a pumps and valves maker, a pharma excipients maker and a two wheelers maker.
This list covers three pump, excipient and commuter bike stocks with complete current figures: Kirloskar Brothers, Sudeep Pharma and Hero MotoCorp. Every figure comes from the latest reported financials and the 9 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pump, Excipient and Commuter Bike Stocks?
Pump, excipient and commuter bike stocks are listed companies that manufacture pumps, valves and fluid handling systems, make pharmaceutical excipients and nutrition ingredients, and build motorcycles and scooters. Their earnings depend on water and industrial projects, ingredient orders and two wheeler sales.
Pump, Excipient and Commuter Bike Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Kirloskar Brothers | 1,649.8 | 13,186 | 35.0 | 43.0 | 15.2 | 0.10 |
| Sudeep Pharma | 1,212 | 11,352 | 61.8 | 35.1 | 19.6 | 0.17 |
| Hero MotoCorp | 5,478 | 100,778 | 18.4 | 23.4 | 26.6 | 0.04 |
On valuation, Kirloskar Brothers and Hero MotoCorp trade at a P/E below the industry P/E, while Sudeep Pharma trades above it, which reflects the growth the market already expects. Readers comparing pump, excipient and commuter bike stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in pump, excipient and commuter bike stocks can use the coming numbers to test whether growth is holding.
Why Do Pump, Excipient and Commuter Bike Stocks Have a Strong Roadmap in India?
Pump, excipient and commuter bike stocks have a strong roadmap in India because heavy spending on water and farm projects, growing global demand for quality pharma ingredients and rising mobility needs keep widening the market for these companies.
- Pumps. Water and farm projects need dependable pumps.
- Excipients. Every tablet and capsule needs quality inputs.
- Two wheelers. Families rely on motorcycles and scooters.
Why Kirloskar Brothers Features Among These Pump, Excipient and Commuter Bike Stocks
Among the pump, excipient and commuter bike stocks on this list, Kirloskar Brothers is a Pune-based maker of pumps, valves and hydro systems used in irrigation, water supply, power plants, buildings and industry. It has served customers for over a century.
In the June 2026 quarter, revenue grew 12.5% year on year to Rs 1,120 crore. Revenue rose from Rs 3,090 crore in FY22 to Rs 4,615 crore in FY26, a compound annual growth rate of 10.5%.
Net profit grew from Rs 81.5 crore in FY22 to Rs 361 crore in FY26, which works out to a compound annual growth rate of 45.1%. The company has a return on equity of 15.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 13,186 crore. The stock trades at a P/E of 35.0, below the industry P/E of 43.0.
Roadmap: The company benefits from public spending on water supply, irrigation and urban infrastructure, and it is growing its project and aftermarket business. A deep service network supports repeat orders.
What to watch: Follow order inflows from water and irrigation projects and the share of aftermarket sales.
Why Sudeep Pharma Features Among These Pump, Excipient and Commuter Bike Stocks
Among the fluid machine, pharma input and two wheeler shares on this list, Sudeep Pharma makes pharmaceutical excipients, food ingredients and nutritional additives such as minerals and fortification products for domestic and global customers.
The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1.
Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore.
Roadmap: Excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.
What to watch: Check capacity expansion progress and export revenue growth.
Why Hero MotoCorp Features Among These Pump, Excipient and Commuter Bike Stocks
Among the three companies on this list, Hero MotoCorp is one of the world’s largest two-wheeler makers by volume, selling motorcycles and scooters across India through a vast network of dealers and service points, and it also exports to several markets.
Revenue rose from Rs 30,106 crore in FY22 to Rs 48,469 crore in FY26, a compound annual growth rate of 12.6%. Net profit grew from Rs 2,329 crore in FY22 to Rs 5,776 crore in FY26, which works out to a compound annual growth rate of 25.5%.
In the June 2026 quarter, revenue grew 35.4% year on year to Rs 13,586 crore. The company has a return on equity of 26.6%, a debt to equity ratio of 0.04 and a market capitalisation of Rs 100,778 crore. The stock trades at a P/E of 18.4, below the industry P/E of 23.4.
Roadmap: The company is widening its premium motorcycle range, building an electric vehicle presence and growing its exports. Its large rural and semi-urban reach supports demand when household spending improves.
What to watch: Track monthly volumes, premium mix, electric vehicle progress and rural demand.
Kirloskar Brothers vs Sudeep Pharma vs Hero MotoCorp on Key Financials
The table below sets the three pump, excipient and commuter bike stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Kirloskar Brothers | 3,090 | 4,615 | 10.5% | 361 | 7.8% |
| Sudeep Pharma | 350 | 671 | 17.6% | 174 | 26.0% |
| Hero MotoCorp | 30,106 | 48,469 | 12.6% | 5,776 | 11.9% |
Hero MotoCorp posts the highest return on equity in this group at 26.6%. Hero MotoCorp has the largest FY26 revenue at Rs 48,469 crore, and Sudeep Pharma shows the fastest revenue growth with a 17.6% compound annual rate. A useful habit with pump, excipient and commuter bike stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Kirloskar Brothers | 995 | 1,120 | 12.5% |
| Sudeep Pharma | 130 | 164 | 25.9% |
| Hero MotoCorp | 10,038 | 13,586 | 35.4% |
Key Risks to Check Before Investing in Pump, Excipient and Commuter Bike Stocks
Every theme carries risks that deserve a check before any decision. For these pump, excipient and commuter bike stocks, the main points are: Long-term fluid machine, pharma input and two wheeler shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Government spending. Public project funding can shift between periods.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pump, excipient and commuter bike stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pump, Excipient and Commuter Bike Stocks
Pump, excipient and commuter bike stocks reward investors who follow demand trends, order books and margins together. Kirloskar Brothers, Sudeep Pharma and Hero MotoCorp each have a clear plan to grow. Based on the 9 November 2026 close, Kirloskar Brothers trades at Rs 1,649.8, Sudeep Pharma at Rs 1,212 and Hero MotoCorp at Rs 5,478. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pump, excipient and commuter bike stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pump, excipient and commuter bike stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pump, excipient and commuter bike stocks?
Ans. Pump, excipient and commuter bike stocks are listed companies that manufacture pumps, valves and fluid handling systems, make pharmaceutical excipients and nutrition ingredients, and build motorcycles and scooters. Their earnings depend on water and industrial projects, ingredient orders and two wheeler sales. This list looks at three of them, Kirloskar Brothers, Sudeep Pharma and Hero MotoCorp, using reported FY22 to FY26 financials and the 9 November 2026 closing prices.
Which pump, excipient and commuter bike stocks are covered in this list?
Ans. This list covers Kirloskar Brothers, Sudeep Pharma and Hero MotoCorp. Based on the 9 November 2026 close, Kirloskar Brothers traded at Rs 1,649.8, Sudeep Pharma at Rs 1,212 and Hero MotoCorp at Rs 5,478. Their return on equity ranges from 15.2% to 26.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.5% to 17.6%.
Why do pump, excipient and commuter bike stocks have a strong future roadmap in India?
Ans. Pump, excipient and commuter bike stocks have a strong roadmap in India because heavy spending on water and farm projects, growing global demand for quality pharma ingredients and rising mobility needs keep widening the market for these companies. The main drivers are as follows. Pumps. Water and farm projects need dependable pumps. Excipients. Every tablet and capsule needs quality inputs. Two wheelers. Families rely on motorcycles and scooters. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Kirloskar Brothers performed financially?
Ans. Revenue rose from Rs 3,090 crore in FY22 to Rs 4,615 crore in FY26, a compound annual growth rate of 10.5%. Net profit grew from Rs 81.5 crore in FY22 to Rs 361 crore in FY26, which works out to a compound annual growth rate of 45.1%. In the June 2026 quarter, revenue grew 12.5% year on year to Rs 1,120 crore. The company has a return on equity of 15.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 13,186 crore. The stock trades at a P/E of 35.0, below the industry P/E of 43.0. Looking ahead, the company benefits from public spending on water supply, irrigation and urban infrastructure, and it is growing its project and aftermarket business. A deep service network supports repeat orders.
How has Sudeep Pharma performed financially?
Ans. Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1. Looking ahead, excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.
How has Hero MotoCorp performed financially?
Ans. Revenue rose from Rs 30,106 crore in FY22 to Rs 48,469 crore in FY26, a compound annual growth rate of 12.6%. Net profit grew from Rs 2,329 crore in FY22 to Rs 5,776 crore in FY26, which works out to a compound annual growth rate of 25.5%. In the June 2026 quarter, revenue grew 35.4% year on year to Rs 13,586 crore. The company has a return on equity of 26.6%, a debt to equity ratio of 0.04 and a market capitalisation of Rs 100,778 crore. The stock trades at a P/E of 18.4, below the industry P/E of 23.4. Looking ahead, the company is widening its premium motorcycle range, building an electric vehicle presence and growing its exports. Its large rural and semi-urban reach supports demand when household spending improves.
What risks should investors check before buying pump, excipient and commuter bike stocks?
Ans. Investors should check a few risks before buying pump, excipient and commuter bike stocks. Government spending. Public project funding can shift between periods. Regulatory approvals. Plant inspections and approvals can affect supplies. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pump, excipient and commuter bike stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 9 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
